These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 27548475)
1. Evaluation of Galectin-3 as a Novel Biomarker for Chagas Cardiomyopathy. Noya-Rabelo MM; Larocca TF; Macêdo CT; Torreão JA; Souza BS; Vasconcelos JF; Souza LE; Silva AM; Ribeiro Dos Santos R; Correia LC; Soares MB Cardiology; 2017; 136(1):33-39. PubMed ID: 27548475 [TBL] [Abstract][Full Text] [Related]
2. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker. Besler C; Lang D; Urban D; Rommel KP; von Roeder M; Fengler K; Blazek S; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28288987 [TBL] [Abstract][Full Text] [Related]
3. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565 [TBL] [Abstract][Full Text] [Related]
4. Galectin-3 (Gal-3) and the tissue inhibitor of matrix metalloproteinase (TIMP-2) as potential biomarkers for the clinical evolution of chronic Chagas cardiomyopathy. Menezes CADS; de Oliveira ALG; Barbosa ICM; de Jesus ACP; Chaves AT; Rocha MODC Acta Trop; 2024 Apr; 252():107153. PubMed ID: 38373528 [TBL] [Abstract][Full Text] [Related]
5. Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms. Numano F; Shimizu C; Jimenez-Fernandez S; Vejar M; Oharaseki T; Takahashi K; Salgado A; Tremoulet AH; Gordon JB; Burns JC; Daniels LB Int J Cardiol; 2015 Dec; 201():429-37. PubMed ID: 26313861 [TBL] [Abstract][Full Text] [Related]
6. Association of Cardiac Galectin-3 Expression, Myocarditis, and Fibrosis in Chronic Chagas Disease Cardiomyopathy. Souza BSF; Silva DN; Carvalho RH; Sampaio GLA; Paredes BD; Aragão França L; Azevedo CM; Vasconcelos JF; Meira CS; Neto PC; Macambira SG; da Silva KN; Allahdadi KJ; Tavora F; de Souza Neto JD; Dos Santos RR; Soares MBP Am J Pathol; 2017 May; 187(5):1134-1146. PubMed ID: 28322201 [TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531 [TBL] [Abstract][Full Text] [Related]
8. Galectin-3 as a candidate upstream biomarker for quantifying risks of myocardial ageing. Keng BMH; Gao F; Ewe SH; Tan RS; Teo LLY; Xie BQ; Koh WP; Koh AS ESC Heart Fail; 2019 Oct; 6(5):1068-1076. PubMed ID: 31392851 [TBL] [Abstract][Full Text] [Related]
9. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. Vergaro G; Del Franco A; Giannoni A; Prontera C; Ripoli A; Barison A; Masci PG; Aquaro GD; Cohen Solal A; Padeletti L; Passino C; Emdin M Int J Cardiol; 2015 Apr; 184():96-100. PubMed ID: 25697876 [TBL] [Abstract][Full Text] [Related]
10. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913 [TBL] [Abstract][Full Text] [Related]
11. Assessment of Galectin-3 Polymorphism in Subjects with Chronic Chagas Disease. Cruz Gda S; Angelo AL; Larocca TF; Macedo CT; Noya-Rabelo M; Correia LC; Torreão JA; Souza BS; Santos RR; Soares MB Arq Bras Cardiol; 2015 Nov; 105(5):472-8. PubMed ID: 26312551 [TBL] [Abstract][Full Text] [Related]
12. Galectin-3 Associated with Severe Forms and Long-term Mortality in Patients with Chagas Disease. Fernandes F; Moreira CHV; Oliveira LC; Souza-Basqueira M; Ianni BM; Lorenzo CD; Ramires FJA; Nastari L; Cunha-Neto E; Ribeiro AL; Lopes RD; Keating SM; Sabino EC; Mady C Arq Bras Cardiol; 2021 Feb; 116(2):248-256. PubMed ID: 33656072 [TBL] [Abstract][Full Text] [Related]
13. Circulating Galectin-3 Levels Are Persistently Elevated After Heart Transplantation and Are Associated With Renal Dysfunction. Grupper A; Nativi-Nicolau J; Maleszewski JJ; Geske JR; Kremers WK; Edwards BS; Kushwaha SS; Pereira NL JACC Heart Fail; 2016 Nov; 4(11):847-856. PubMed ID: 27614937 [TBL] [Abstract][Full Text] [Related]
14. Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. Fenster BE; Lasalvia L; Schroeder JD; Smyser J; Silveira LJ; Buckner JK; Brown KK Heart Vessels; 2016 Jun; 31(6):939-46. PubMed ID: 25976729 [TBL] [Abstract][Full Text] [Related]
15. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience. Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834 [TBL] [Abstract][Full Text] [Related]
16. Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Rutherford E; Talle MA; Mangion K; Bell E; Rauhalammi SM; Roditi G; McComb C; Radjenovic A; Welsh P; Woodward R; Struthers AD; Jardine AG; Patel RK; Berry C; Mark PB Kidney Int; 2016 Oct; 90(4):845-52. PubMed ID: 27503805 [TBL] [Abstract][Full Text] [Related]
17. Echocardiographic diagnosis and evaluation of cardiomyopathies: idiopathic hypertrophic subaortic stenosis, Chagas' heart disease and endomyocardial fibrosis. Hernández-Pieretti O Postgrad Med J; 1977 Sep; 53(623):533-6. PubMed ID: 412175 [TBL] [Abstract][Full Text] [Related]